Betamethasone enemas effective in intestinal GVHD
1
Inpharma 1318 - 15 Dec 2001 ■ Betamethasone enemas effectively treated refractory and severe intestinal GVHD (graft-versus- host disease), report researchers from Japan. In this study, 8 patients with systemic corticosteroid-resistant GVHD after allogeneic bone marrow transplantation received betamethasone [‘Steronema’] 3.95mg enemas once or twice daily for 5–27 days. In 6 patients, diarrhoea and/or abdominal pain resolved and, after the enemas were discontinued, the systemic corticosteroid dosages were successfully reduced without recurrence of intestinal GVHD. The researchers say that the enemas were well tolerated by all patients except one, whose general condition was poor. Wada H, et al. Treatment of intestinal graft-versus-host disease using betamethasone enemas. Transplantation 72: 1451-1463, 27 Oct 2001 800886462 1 Inpharma 15 Dec 2001 No. 1318 1173-8324/10/1318-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Betamethasone enemas effective in intestinal GVHD
Inpharma 1318 - 15 Dec 2001
■ Betamethasone enemas effectively treatedrefractory and severe intestinal GVHD (graft-versus-host disease), report researchers from Japan. In thisstudy, 8 patients with systemic corticosteroid-resistantGVHD after allogeneic bone marrow transplantationreceived betamethasone [‘Steronema’] 3.95mg enemasonce or twice daily for 5–27 days. In 6 patients,diarrhoea and/or abdominal pain resolved and, afterthe enemas were discontinued, the systemiccorticosteroid dosages were successfully reducedwithout recurrence of intestinal GVHD. Theresearchers say that the enemas were well tolerated byall patients except one, whose general condition waspoor.Wada H, et al. Treatment of intestinal graft-versus-host disease usingbetamethasone enemas. Transplantation 72: 1451-1463, 27 Oct2001 800886462
1
Inpharma 15 Dec 2001 No. 13181173-8324/10/1318-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
![State-of-the-art acute and chronic GVHD treatment · β and IL10 also have regulatory roles in GVHD [45, 46]. The third step in the GVHD pathophysiology is the effec-tor phase. It](https://static.fdocuments.us/doc/165x107/5f128375ac35905de301ce2b/state-of-the-art-acute-and-chronic-gvhd-treatment-and-il10-also-have-regulatory.jpg)
